A program to lead cancer research and clinical trials at Dana-Farber Cancer Institute.
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
This study at Dana-Farber is all about helping cancer patients by offering them access to new and exciting treatments through clinical trials, so they can benefit from the latest research and potentially improve their care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10796969 on NIH RePORTER |
What this research studies
This initiative at Dana-Farber/Partners Cancer Care focuses on reducing the burden of cancer by leading and participating in clinical trials through the National Clinical Trials Network. It involves a collaborative effort among top cancer researchers and clinicians from major teaching hospitals to enhance patient access to innovative cancer treatments. Patients may be enrolled in various clinical trials that address a wide range of cancer types, including both common and rare malignancies. The program aims to contribute to the development of new therapies and improve existing treatment protocols.
Who could benefit from this research
Good fit: Ideal candidates for participation include adults diagnosed with breast cancer, lung cancer, leukemia, and other malignancies who are seeking access to cutting-edge clinical trials.
Not a fit: Patients with conditions unrelated to cancer or those who are not eligible for clinical trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments and better outcomes for patients diagnosed with various types of cancer.
How similar studies have performed: Previous research initiatives within the National Clinical Trials Network have shown success in improving cancer treatment outcomes, indicating that this approach is both tested and effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Burstein, Harold John — Dana-Farber Cancer Inst
- Study coordinator: Burstein, Harold John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.